Penson, D. F., Armstrong, A. J., Concepcion, R. S., Agarwal, N., Olsson, C. A., Karsh, L. I., … Higano, C. S. (2022). Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer Prostatic Dis, 25(3), 597. https://doi.org/10.1038/s41391-021-00477-3

Penson, David F., Andrew J. Armstrong, Raoul S. Concepcion, Neeraj Agarwal, Carl A. Olsson, Lawrence I. Karsh, Curtis J. Dunshee, et al. “Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.” Prostate Cancer Prostatic Dis 25, no. 3 (September 2022): 597. https://doi.org/10.1038/s41391-021-00477-3.

Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, et al. Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):597.

Penson, David F., et al. “Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.” Prostate Cancer Prostatic Dis, vol. 25, no. 3, Sept. 2022, p. 597. Pubmed, doi:10.1038/s41391-021-00477-3.

Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):597.